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Introduction
Nucleosides, due to their biological role as constituents of nucleic acids, are main targets
in the development of analogues aimed at antimetabolite-based therapy. Modified nucleo-
sides can disrupt biological processes causing the death of cancer or virally-infected cells.
10 Fluorinated analogues of biologically active compounds are often characterized by a
dramatic change in their activity, compared with the parent molecules. Fluorine, the most
electronegative element, is isosteric with a hydroxy group, the C-F bond length (1.35 A

)
being similar to the C-O bond length (1.43 A

). In addition, it is the second smallest atom and
it can mimic hydrogen in a modified structure; its van derWaals radius (1.47 A

) is intermedi-
15 ate between that of hydrogen (1.20 A

) and that of oxygen (1.52 A

). The strength of the C-F
bond exceeds that of C-H bond and for this reason organofluorine compounds are often bio-
logically and chemically more stable than their corresponding natural compounds.
In the case of nucleosides and their analogues, fluorine atoms can be introduced
either in the nucleobase or in the sugar moiety. An example of the first type modification
20 is capecitabine1 (N4-pentyloxycarbonyl-50-deoxy-5-fluorocytidine), a 5-fluoropyrimidine
nucleoside approved as a drug against colorectal, gastric and breast tumors; gemcitabine2
(20-deoxy-20,20-difluorocytidine) is an example of a nucleoside fluoro-modified in the
sugar moiety, approved as a drug against solid tumors.
The aim of this review is to discuss the synthesis of antitumor pyrimidine nucleosides
25 containing fluorine atoms in either the nucleobase or the sugar moiety. Because of the
ongoing need of new antitumor chemotherapies, over the years many fluorinated pyrimi-
dine nucleosides have been prepared in order to assay their activity. The synthesis of
these compounds has thus been driven largely by results on their biological potential.
Nonetheless, it is important for experimentalists to be aware of the full range of methods
30 used, whether or not the compounds synthesized have actually demonstrated antitumor
activity. It is our hope, then, that researchers investigating fluoropyrimidines for purposes
other than their anticancer properties will also find this article useful.
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I. Fluoropyrimidines
1. 5-Fluorouracil
35 Interest in the fluoropyrimidines stemmed from studies of the metabolism of uracil in rat
hepatoma cells. The observation that these cells utilize uracil more avidly than normal rat
intestinal mucosa prompted the preparation of fluorinated pyrimidines in order to improve
disruption of tumor DNA biosynthesis.3
In 1957 5-fluorouracil (5-FU) 1 was synthesized by Heidelberger et al.,4 with the aim of
40 blocking metabolism in malignant cells. The replacement of a hydrogen atom at C-5 by the
fluorine atommodifies the interaction with the active sites of enzymes involved in metabolism.
This antimetabolite, although toxic, is still one of themost widely used agents against solid
tumors. Its action is due to two different mechanisms:5 after penetration into the cell, 5-FU 1 is
transformed into the 5-fluorouridine triphosphate that mimics UTP, is recognized by RNA
45 polymerase and consequently incorporated into RNA. The most significant action, however, is
due to the 5-FU conversion into 5-fluoro-20-deoxyuridine (FdUMP) 2, a known inhibitor of thy-
midylate synthetase (TS), a key enzyme in the DNA synthesis.6,7 TS, in the presence of methy-
lene tetrahydrofolate and deoxyuridine monophosphate (dUMP) 3 forms a ternary complex
that catalyzes the substitution of 5-H uracil with a methyl group, affording thymine. If FdUMP
50 2 is present, the above ternary complex is not able to carry out this reaction, due to the presence
of fluorine in the 5-position: the formation of TMP 4 (20-deoxythymidine 50-monophosphate),
the only nucleotide precursor specific to DNA, is, therefore, blocked (Scheme 1), decreasing
the availability of TTP (20-deoxythymidine 50-triphosphate) for DNA synthesis.
Scheme 1
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Later two additional mechanisms were proposed for 5-FU 1 antitumor activity: the
55 incorporation of 5-FU into DNA and the alteration of the membrane function of 5-FU 1
treated cells. Recent studies indicate that the TS-direct mechanism predominates when 1
is administered at low doses for a prolonged time, whereas the RNA-mediated process is
more active following a bolus administration.8–10
Synthesis of 5-FU 1, by construction of the pyrimidine ring, was first realized by Hei-
60 delberger et al. in 19574,11,12 by reaction of a thiourea derivative 5 with the enolate of
ethyl a-fluoro, a-formyl acetate 6 which, in turn, was obtained from methyl formate and
ethyl fluoroacetate (Scheme 2). Depending on the chosen a-fluoro-b-ketoester the method
is also applicable to the synthesis of other 5-fluoropyrimidines.
An alternative method for the total synthesis is the direct fluorination of the pyrimi-
65 dine ring of compound 7 by means of trifluoromethyl hypofluorite (CF3OF)
13 proposed
by Robins in 1971. In the case of CF3OF in methanol/fluorotrichloromethane an interme-
diate was formed that, after treatment with triethylamine, afforded 5-FU 1 in 84% yield.13
If the reaction was carried out with CF3OF in trifluoroacetic acid 1 was directly isolated in
85% yield.14 The method proposed by Robins13 is suitable also for the direct introduction
70 of fluorine on preformed nucleosides, for example compound 8 (Scheme 3).
Scheme 2
Scheme 3
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The mechanism of the reaction with CF3OF in methanol followed by treatment with
triethylamine was later investigated by Robins et al.15 who assigned the structure of
(§)-cis-5-fluoro-6-methoxy-5,6-dihydrouracil to intermediate 9 that, by treatment with
triethylamine, afforded 5-FU 1 (Scheme 4).
76
80
85
The use of fluorine as fluorinating agent16,17 requires efficient dissipation of the heat of
reaction, in order to avoid the destruction of the carbon skeleton of pyrimidine. This result
can be achieved by bubbling a mixture of fluorine and an inert gas through a cold liquid,
90 or removing the heat of reaction by carrying out the reaction in the presence of a metal
packing or, finally, by addition of very large amount of an inert diluent gas. This last pro-
cedure is the most followed and usually fluorine is diluted with an equal amount of nitro-
gen and then passed through the reaction mixture. 5-FU 1 was obtained in 92.4% yield16
and sublimation at 190C and 1 mm Hg provided a highly pure product.17
95 Xenon difluoride can be used for direct fluorination of the pyrimidine ring but it is diffi-
cult to handle due to its high reactivity; in 1980 Kagan et al. realized the direct fluorination
of uracil 7 employing C19XeF6, which is much more stable than free xenon hexafluoride.
18
Uracil 7was the startingmaterial of the above described direct fluorinationmethods.13–18
In a method patented in 1979,19 cytosine 10was fluorinated by means of fluorine fluorosulfo-
100 nate (FOSO2F) diluted with nitrogen (60%) affording 5-FU 1 (87.7% yield) (Scheme 5).
Scheme 4
Scheme 5
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Orotic acid20 11 was, instead, the starting material for a synthesis of 5-FU by a com-
bination of a fluorination and a decarboxylation (Scheme 6). In the course of the reaction
an intermediate was formed that can be converted into 5-fluoro orotic acid 12 (in boiling
water) which was, in turn, transformed into 5-FU by heating at 240C.
105 Starting from the methyl ester of uracil 5-carboxylic acid 13 the synthesis of 5-FU 1 was
realized in one-pot, in excellent yield (92%), by addition of a reducing agent (sodium bisulfite)
aimed to exclude the formation of peroxides by reaction of water with fluorine (Scheme 7).21,22
A different approach to the synthesis of 1 provided the substitution of the halo atoms of the
2,4,5-trichloropyrimidine or 2,4-dichloro,5-bromopyrimidine 14 by means of potassium fluo-
110 ride at 400C to afford the corresponding 2,4,5-trifluoropyrimidine 15; its treatment with
sodium hydroxide in water at 80C gave the desired 5-FU 1.23 The starting 2,4,5-trihalopyrimi-
dine 14was obtained fromuracil 7 by reactionwith chlorine, or bromine, followed by treatment
of the 5-halouracil 16with phosphoryl chloride (76 or 82%, respectively) (Scheme 8).
Scheme 6
Scheme 7
Scheme 8
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Some years later a similar approach24 starting from tetrafluoropyrimi-
115 dine25 17, was described by Baasner et al. 4,6-Dichloro-2,5-difluoropyrimidine
18 was obtained in 64% yield from tetrafluoropyrimidine 17 by reaction with
gaseous hydrogen chloride. Chlorine in the 6-position was selectively
removed by hydrogenation in the presence of palladium on carbon in ethyl
acetate and triethylamine (70.5% yield). The resulting 4-chloro-2,5-difluoro-
120 pyrimidine 19 was hydrolyzed with sodium hydroxide in water affording 5-FU
1 in 93% yield.
Direct fluorination of uracil continued to be of interest. In 1981 a method based on
the use of fluorine/nitrogen in acetic acid was proposed: the intermediate 6-acetoxy-5-flu-
oro-5,6-dihydrouracil 20, obtained in 70% yield, was converted into the desired 5-FU 1
125 by acetic acid elimination.26 (Scheme 9).
In a similar approach the use of fluorine diluted with helium in aqueous phos-
phoric acid27 (Scheme 9) afforded 5-FU 1 in 84.5%. The advantages of this method
are the low cost of phosphoric acid, the capability of its solution to work as an
adsorbent of the by-product hydrogen fluoride and to precipitate the final product as
130 crystals.
Another fluorinating agent, acetyl hypofluorite, (generated in situ from fluo-
rine and acetic acid) was studied, in comparison with fluorine in acetic acid,
from a mechanistic point of view.28 The two geometric isomers of 5-fluoro-6-ace-
toxyuracil 20 were isolated as reaction intermediates; their configuration cannot
135 be assigned by 1H and 19F NMR spectra since the coupling constants of cis and
trans compounds are too similar. Only one of the isomers, by addition of acetate
ion, was transformed into 5-FU 1, acetate being a strong enough base to facilitate
acetic acid elimination. The cis and trans configurations were assigned consider-
ing that in the cis isomer the H atom and the acetate group are in trans position,
140 which is the favored one for the elimination of acetic acid. In presence of trie-
thylamine both isomers afforded 5-FU 1 (Scheme 10).
Scheme 9
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Visser et al.29–30 also studied the mechanism and the stereochemistry of uracil 7 fluorination
145 with fluorine or acetyl hypofluorite, proposing that addition at the 5–6 double bond occurs
through radical anion 21; formed 5-fluoro-6-acetoxy derivative 20 evolves into the final prod-
uct through an intermediate that in the presence of a base affords final 5-FU 129 (Scheme 11).
The influence of the N-1 substituent on the stability of 5-fluoro-6-acetoxy intermedi-
ate31 and conversion by reaction with alcohols were also studied.30
150 A commercially available, stable, easy to handle fluorinating agent, SELECT-
FLUOR, was proposed in 1995 for the synthesis of fluorohydrin 22 that, by sublimation,
provided 5-FU 1 (82%)32 (Scheme 12).
Scheme 10
Scheme 11
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Some approaches avoiding the direct fluorination are reported in the literature. For
example, starting from s-triazine 23, it is possible to prepare 5-FU 1 (88% yield) by reac-
155 tion of fluoroacetamide and lithium diisopropylamide (Scheme 13).33
Diethyl fluoromalonate (prepared from trifluoroacrylic acid) was easily converted to
5-fluoro-6-chlorouracil 25 by reaction with urea to afford 5-fluorobarbituric acid 24 (97%
yield) followed by reaction with phosphoryl chloride in dimethylaniline (46% yield). The
6-chlorine atom of 25 was removed by hydrogenolysis (Pd/C) affording 5-FU 1 in 73–
160 91% yield, depending on the reaction conditions (Scheme 14).34
The methyl ester of 2-fluoro-3-methoxy acrylic acid 26 can be used as a synthon of the
fluorinated uracil ring: by reaction with O-(trimethylsilyl)urea intermediate 27 was formed
that by cyclization with sodium hydroxide afforded 5-FU 1 (67% yield) (Scheme 15).35
Scheme 12
Scheme 13
Scheme 14
Scheme 15
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Recently,36 5-FU 1 was prepared by deamination of 5-fluorocytosine 28 by means of
165 a new 5-methylcytosine deaminase: expression of deaminase in E. coli caused an efficient
transformation of non-toxic 5-fluorocytosine 28 into 5-FU 1 that abolished or severely
inhibited growth of cells. The goal of this study was, of course, to transfect cancer cells
with the deaminase (Scheme 16).
5-FU 1, since its introduction more than 50 years ago, has become a component of
170 therapy for gastrointestinal, head and neck and breast cancers. The activity of 5-FU is lim-
ited by its rapid degradation into 5,6-dihydro-5-fluorouracil (5-FUH2) 29 under the action
of dihydropyrimidine dehydrogenase (DPD), an enzyme NADPH-dependent
(Scheme 17).5 It has been demonstrated that this enzyme deactivates more than 85% of
the injected 5-FU 1.
175 At the beginning 5-FU 1 was administered by intravenous bolus but its low bio-
logical t1/2 makes continuous infusion more convenient. The use of oral 5-FU 1 was
abandoned some decades ago because of its irregular absorption, due to intra- and
inter-individual differences depending on the variable activity of dihydropyrimidine
dehydrogenase. In addition to the inconvenience of i.v. administration, the efficiency
180 of 5-FU 1 is limited by its toxicity due to phosphorylation in the digestive tract and
to the lack of selectivity toward tumors. The development of 5-FU 1 derivatives was
the target of many studies. The toxicity of 5-FU 1 can be reduced by derivatives
which are stable to enzymatic degradation, by derivatives that inhibit DPD or by
prodrugs of 1 that liberate the active principle in tumor cells. A prodrug is defined
185 as a pharmacologically inactive compound that is converted into an active agent by
metabolic transformations. The prodrugs of 5-FU 1 are characterized by a pyrimidine
ring bearing a fluorine atom in the 5 position. The main benefit is oral administra-
tion, with the improvement in quality of life of the patient.
Scheme 16
Scheme 17
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In the present review we now describe some derivatives in which 5-FU 1 is conju-
190 gated to drug carriers or molecules endowed with antitumor activity.
2. 5-Fluorouracil Derivatives
In 1985 N1-(3-aminopropyl)-5-fluoro uracil 30 was synthesized from 5-FU 1 by treatment
with hexamethyldisilazane and trimethylchlorosilane followed by reaction with N-(3-bro-
mopropyl)-phthalimide. Deprotection afforded the desired product in 54% yield. The
195 amino derivative was considered a suitable precursor of N1-(2-formylethyl)-5-fluorouracil
31, which may be converted to 5-FU following an enzymatic reaction. Indeed, in presence
of amine oxidase the amine was transformed into 5-FU 1 and acrolein, in the course of
24 h incubation. The slow enzymatic conversion, however, indicated that 5-FU-derivative
30 might not be efficiently metabolized in vivo (Scheme 18).37
200 A mutual prodrug consists of two synergistic drugs joined together. The two mole-
cules may be connected directly or by means of a linker: in 1997 work38 5-FU 1 was
linked to cytarabine 32, an antitumor agent used mainly in the treatment of acute leuke-
mia and lymphomas, affording compound 33. Cytarabine (ara-C) 32 is attached to the
double drug through a hydrolyzable amide bond, while 5-FU is attached via an acyloxy-
205 methylene group, easily removable. Two spacers with different length (two or four meth-
ylene groups) were used and the synthesis is outlined in Scheme 19. The synthesis
afforded the product with yield ranging from moderate to excellent; and, after the intro-
duction of 5-FU 1, mild conditions and selective reagents, due to the formation of the
labile N-O ketal derivative, were required. The benzenesulfenyl chloride, by-product of
210 the preparation of chloromethylester 34, was removed by trapping it with cyclohexene-
1,2-dicarboxylic acid, instead of the usual cyclohexene, in order to remove the addition
product by an aqueous washing. This avoided separation by distillation of products hav-
ing similar boiling points. Final compound 33 with nD 4 was stabler than the correspond-
ing compound with n D 2, over a wide range of pH, and for this reason it was estimated to
215 be more suitable for biological testing.
Scheme 18
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More recently39 another mutual prodrug of 5-FU 1 was developed with diazenium-
diolates, which are known to be controlled sources of NO. NO can inhibit metastasis,
enhance cancer cells apoptosis and assist macrophages to kill tumor cells. Two different
conjugates, with methylene or acyloxymethylene as spacers, were synthesized starting
220 from sodium 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (PYRRO/NO) 35 in turn pre-
pared according to a procedure already reported.40 The key intermediate of the two
syntheses was the O2-chloromethyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (chloro-
methyl PYRRO/NO) 36 that by direct reaction with 5-FU 1 or through its succinic acid
derivative 37 afforded the desired products 38 together with the N1,N5-bisalkylation prod-
225 ucts 39 (Scheme 20). The two mono-alkylated conjugates were evaluated in hydrolysis by
monitoring the NO release. Both prodrugs showed greater activity than 5-FU, but the
Scheme 19
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compound with methylene as spacer was very stable in aqueous solution and no substan-
tial NO was detected. On the contrary the other prodrug with a longer spacer released NO
both at pH 8 and in the presence of esterase.
Scheme 20
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230 In order to enhance the delivery characteristics of 5-FU 1 a series of N-acyl and
N-alkoxycarbonyl derivatives were prepared and their antitumor activity
evaluated.41,42
According to a 1980 article41, the most promising antitumor agent, even when
administered orally, was the N1-acetyl-N3-ortho-toluyl-5-fluorouracil 40. The paper
235 described the different acylated products that can be obtained depending on the
chosen acylating agent, solvent and reaction temperature. N1-Acetyl-N3-ortho-
toluyl-5-FU 40 was prepared starting from N1-acetyl derivative 41 by reaction with
ortho-toluyl chloride in dioxane and triethylamine. The N3-ortho-toluyl derivative
of 5-FU, 42, was isolated in mice serum when N1-acetyl-N3-ortho-toluyl-5-FU 40
240 was orally administered. In order to obtain this N3-monosubstituted compound 42
the best conditions used ortho-toluyl chloride in pyridine at room temperature
(Scheme 21).
Further, the N1-alkoxycarbonyl derivatives42 prepared from 5-FU 1 by reaction
with the appropriate chloroformates in pyridine were hydrolyzed in serum affording
245 the 5-FU 1.
b-Lactam based prodrugs, in particular cephalosporin-based prodrugs, have
been reported in the past and in 200943 this approach was also applied to
5-FU 1. The 5-FU-cephalosporin conjugate was synthesized starting from the
N1-BOC-5-FU 43 and the suitably functionalized cephem 44 (Scheme 22),
250 affording a compound stable in aqueous media; conjugate 45 in the presence
of b-lactamase was completely cleaved to 5-FU 1 and the hydrolyzed cephalo-
sporin, demonstrating its strategic potential against a range of human carci-
noma cells.
The observation that the phthalide fragment was widely used in the creation
255 of transport forms of antibiotics prompted the introduction of this moiety in the
Scheme 21
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5-FU 1 molecule.44,45 1-(3-Phthalidyl)-5-fluorouracils were synthesized starting
from the N3-benzoyl-5-FU 4644 or from the bis(trimethylsilyl) derivative of 5-
FU 4745 (Scheme 23). In the first case N3-benzoyl-5-FU 4644 was reacted with
3-bromophthalide in presence of sodium hydride affording phthalide derivative
260 48 in 59% yield. Subsequent acidic hydrolysis gave desired product 49 in 54%
yield. The phthalide derivative was effectively biotransformed into 5-FU 1 in
mice serum. Starting from 2,4-bis(trimethylsylil)-5-fluorouracil 47 45 phthalide
derivative 49 was obtained in 94% yield by reaction with 3-bromo phthalide at
100C.
265 Some 5-FU prodrugs with a removable attachment were also proposed. For example
porphyran 50, a polysaccharide from the red algae Porphyra haitanensis, was employed
as a drug carrier, allowing the fixation at 5-FU 1 at the 6-position through an acetyl spacer
group of polysaccharide derivative 51 (Scheme 24).46 The release of 5-FU 1 from conju-
gate 52 was studied in 0.01M NaOH solution, in 0.1M HCl solution and in phosphate
270 buffer. The amount of released 5-FU 1 was significantly different, and only in basic media
did the prodrug release quickly the 5-FU 1. In vivo studies are not reported.
Scheme 22
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In order to decrease the toxicity of 5-FU 1,2,5-triacetyl-b-D-glucofuranurono-6,3-
lactone 53 was reacted with 2,4-bis(trimethylsylil)-5-fluorouracil 47, according to a
reported method.47 The obtained molecule combines the active principle 5-FU 1 and the
275 nontoxic glucuronic acid, which participates in the detoxification of xenobiotics in the
organism by forming the glucuronides (Scheme 25).48 Biological studies showed that
Scheme 24
Scheme 23
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5-FU derivative 54 has a very low toxicity and a relatively high antitumor activity. At pH
1.4 only the lactone ring undergoes splitting while at pH 7.4 the lactone ring and the
N-glycosidic bond are split with formation of 5-FU 1.
280 The concept of “radioinduced drug” proposed for cancer therapy is also noteworthy: 5-FU
derivatives variously substituted at the 1-position were prepared and the release of the antitumor
drug was observed upon g-irradiation.49 5-FU dimer 5550 and 5-fluoro-1-(20-oxocycloalkyl)-
uracil 5651 released 5-FU 1 by radiation activation under hypoxic conditions (Scheme 26).
5-FU 1 can also be released from gold nanoparticles by photoirradiation.52 In this
285 case 1 was conjugated to gold nanoparticles through a photoresponsive ortho-nitrobenzyl
linkage.
Scheme 25
Scheme 26
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Photoirradiation was also responsible for the recently reported53 release of 5-FU from
oligonucleotide tetramer 58 (Scheme 27). The key reaction was the elimination of a nucleo-
base by photoinduced C10 hydrogen abstraction, in turn caused by the radical (compound
290 59) photo-generated at C5 of the adjacent 5-halouracil. This approach seems to be promising,
since the 5-FU could be released by photoirradiation only in the irradiated area of the body.
Even if they are certainly promising, the 5-FU derivatives described herein have not
yet found application in clinical trials, although some of them are under investigation,
and studies to assess their possible therapeutic use are still in progress.
295 II. Fluoropyrimidine Nucleosides
Among the 5-FU derivatives developed for oral administration, 5-fluoropyrimidine nucleosides
deserve an outstanding position as proven by a 2000 review5 about the 5-FU prodrugs consid-
ered from the clinical point of view. Protracted oral administration should be the ideal route of
administration of 5-FU, being preferred by the patients and by pharmacoeconomic considera-
300 tions. The low oral bioavailability of 5-FU 1 has been overcome by the new generation of oral
fluoropyrimidine nucleosides.54–56 Themain 5-FU prodrugs are depicted in Scheme 28.
Scheme 27
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1. Tegafur (Ftorafur)
Tegafur 60, also known as ftorafur (1-(tetrahydro-furanyl)-5-fluorouracil) is the first
designed 5-FU prodrug. It has a high chemotherapeutic activity (twice that of 5-FU) and
305 low toxicity (5–6 times less than 5-FU) and it is used for the treatment of breast and gas-
trointestinal tract cancer. Typically, it is used in combinations with other drugs to further
improve its bioavailability.54–57 For instance, the combination of uracil 7 and tegafur 60
(4:1), namely UFT, allows for higher levels of circulating 5-FU, by saturating the dihy-
dropyrimidine dehydrogenase with its natural substrate uracil 7.
310 Tegafur was synthesized for the first time in 196958 through the condensation of the
bis(trimethylsilyl) derivative of 5-FU 47 and 2-chlorotetrahydrofuran 64 (Scheme 29) or
by condensation of 5-fluorouracil-mercury and 2-chlorotetrahydrofuran 64 in dimethyl-
formamide and toluene (75%).
2-Chlorotetrahydrofuran 64 was also used by other authors59–61, and its preparation
315 was the object of studies60 that included determination of the best molar ratios61 between
the reagents in order to minimize the formation of the 1,3-bis(tetrahydro-20-furyl)-5-fluo-
rouracil that is the main by-product due to the double condensation reaction.
Scheme 28
Scheme 29
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Tegafur 60 is administered as a racemic mixture, due to no significant differences in
the effects of the stereoisomers, as confirmed by the tests carried out with the separated
320 enantiomers in 1977.62 The separation of enantiomers was achieved by formation of dia-
stereoisomers with brucine (Scheme 30). The racemic mixture of tegafur was, in this
case, prepared in 91% yield, by reaction of 2-acetoxy tetrahydrofuran 65 with the silylder-
ivative of 5-FU 47, using sodium iodide as catalyst.
The same 2-acetoxytetrahydrofuran 65 was also used with typical Friedel-Craft cata-
325 lysts63 or without catalyst at 120C in dimethylformamide (Scheme 31); higher tempera-
tures lead to the degradation either of tegafur 60 or of 2-acetoxytetrahydrofuran 65.64
A different catalyst, cesium chloride, was used in the condensation between disily-
lated 5-FU 47 and 2-acetoxytetrahydrofuran 65, in acetonitrile affording tegafur 60 in
87% yield (Scheme 32).65
Scheme 30
Scheme 31
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330 The most popular tetrahydrofuran derivative in the synthesis of tegafur 60 was, how-
ever, the 2,3-dihydrofuran 66. In a French patent, an excess of this compound was reacted
with 5-FU 1 in aprotic polar solvents affording tegafur 6066 (Scheme 33) with yield
depending on the chosen solvent.
In similar conditions but in the presence of an acidic catalyst (for example triethyl-
335 amine hydrochloride, and tetrabutoxytitanium) 59–89% yields were observed.67 The
same reaction was realized in the presence of phosphorus pentachloride in hexamethyl-
phosphoramide affording tegafur 60 in 88% yield; poor yields were observed changing
the solvent (DMF or DMA) and a decreased regioselectivity was obtained using phospho-
rus trichloride instead of phosphorus pentachloride.68
340 Two patents of two different Japanese companies described the synthesis of tegafur
60 from 5-FU 1 and 2,3-dihydrofuran 66 in the presence of trimethylsilyl chloride and
triethylamine in dimethylformamide69 or in the presence of dimethyldichlorosilane and
triethylamine in acetonitrile.70 The optimization of the molar ratio between 5-FU 1 and
2,3-dihydrofuran 66 and the use of calcium chloride as catalyst, under pressure, afforded
345 very high yields (85–92%) of tegafur 60.71
A one-pot synthesis72 was realized starting from 2,3-dihydrofuran 66 that was treated
with water in the presence of an acidic catalyst (H3PO4, H2SO4, alkylsulfonic acids) at a
pH value below 2.5; after removal of the excess of unreacted material the obtained mix-
ture was treated with the silyl derivative of 5-FU 47 and Friedel-Craft catalyst (SnCl4,
350 BF3, TiCl4, NaI) (Scheme 34).
Scheme 32
Scheme 33
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Depending on the ratio between 2,3-dihydrofuran 66 and 5-FU 1, in pyri-
dine, in a sealed tube, tegafur 60 or 1,3-bis(tetrahydrofuryl)-5-fluorouracil 67
were obtained (Scheme 35).73 Interestingly, the heating of the bis-substituted 5-
FU 67 at 135C for 12 h, at reduced pressure, afforded tegafur in 76% yield.
355 Some different starting materials were also proposed, alternative to the 5-FU or
to the tetrahydrofuran derivatives. For example, the 5-fluoro-6-hydroxy-5,6-dihy-
drouracil 6874 provided, by reaction with hexamethyldisilazane or hexamethyldisila-
zane and trimethylsilyl chloride, bis(trimethylsilyl)-5-fluorouracil 47 (80–82%),
which by further reaction with 2-chlorotetrahydrofuran 64, in THF, afforded tegafur
360 60 (51% yield) (Scheme 36).
Scheme 34
Scheme 35
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A series of 2-alkoxyderivatives was used, the best results being achieved with
the 2-tert-butoxytetrahydrofuran 69 (67% yield).75 The small amount of disubstituted
by-product 67 was quantitatively converted into tegafur by treatment with acetic
acid (Scheme 37).
365 In a different approach, a preformed nucleoside, b-5-fluoro-20-deoxy-uridine 61, was
used as starting material and submitted to the reaction with black platinum in water and
sodium hydrogen carbonate; the recovered 50-carboxyderivative 70 was transformed into
the corresponding methyl ester 71 and the 30-hydroxy group was derivatized as mesylate
72. Simultaneous elimination of 30-O-mesylate and 50-COOCH3 afforded the dihydro-
370 furan ring (compound 73); catalytic hydrogenation gave the (20R) isomer of tegafur 60
(Scheme 38).76 Starting from the a-preformed nucleoside the (20S) enantiomer of tegafur
60 was obtained.
Scheme 36
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The dimethylacetal of 4-hydroxybutanal-4-O-trimethylsilylether 74 was used as pre-
cursor of the tetrahydrofuran ring:77 the acetal was treated with bis(trimethylsilyl)-5-fluo-
375 rouracil 47, in acetonitrile, in the presence of stannic chloride. Tegafur 60 was recovered
in 84% yield (Scheme 39).
bis(Trialkylstannyl)-5-fluoro uracil 7578 was used, instead of the usual silyl deriva-
tive, in the reaction with a series of 2-substituted tetrahydrofurans, in the presence of
Scheme 38
Scheme 39
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different acid catalysts. The formation of desired tegafur 60 (70–95%) was obtained when
380 a 1:1 molar ratio was utilized of 5-FU derivative/2-substituted tetrahydrofuran. In the case
of a molar ratio 1:2 the N1,N3-disubstituted product was isolated. As previously
reported75 N1,N3-disubstituted product 67 was converted into tegafur 60 by acidic treat-
ment (Scheme 40).
As in the case of 5-FU 1 synthesis the direct fluorination of the preformed nucleoside
385 was described. Trifluoromethyl hypofluorite in dichloromethane79 gave the fluorination
of 1-(tetrahydrofuranyl) uracil 76 in 60% yield (Scheme 41).
Using fluorine as fluorinating agent, the reaction with 1-(20-tetrahydrofuryl)-5-meth-
oxycarbonyluracil 77 gave different intermediates depending on the chosen solvent.21,22 In
water 5-fluoro-6-hydroxy intermediate 78 was obtained, while in acetic acid 5-fluoro-6-ace-
390 toxy derivative 79 was formed. Both intermediates led to desired tegafur 60 in 84% and 62%
yield, respectively (Scheme 42) by hydrolysis of the methyl ester and elimination reaction.
Scheme 40
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More recent works about tegafur are especially focused on the improvement of its oral
absorption and biological half-life and to lowering its toxicity. With this aim in mind, a light-
triggered porphyrin tegafur prodrug was developed.80 Porphyrins are photosensitizers used in
395 photodynamic therapy and they tend to accumulate in neoplastic tissue to higher concentra-
tions than in adjacent normal tissue. The porphyrin prodrug was composed of three parts: a
Scheme 42
Scheme 43
Synthesis of Antitumor Fluorinated Pyrimidine Nucleosides 25
porphyrin, a photocleavable ortho-nitro benzyl moiety, as a light-triggered group, and tega-
fur. In vitro tests demonstrated that this prodrug is less toxic than its parent drug and that it
can release cytotoxic tegafur 60 upon photoactivation with long wavelength UV light (350
400 nm). The synthesis of porphyrinic prodrug 80 is depicted in Scheme 43.
2. Floxuridine
Floxuridine 61 (5-fluoro-20-deoxyuridine, FdUrd) (See Scheme 28) is the deoxyribose
metabolite of 5-FU and the precursor of 5-fluorouridine monophosphate 2 (FdUMP) that
inhibits thymidilate synthetase (TS) (See Scheme 1). FdUrd 61 can be also converted into
405 5-FU 1 in the liver by thymidine phosphorylase (TP). It was approved in therapy by the
FDA in 1970 and has been extensively used for the clinical treatment of carcinoma of the
ovary, breast and gastrointestinal tract. Due to the higher toxicity, costs and equal efficacy
compared to 5-FU 1 the use of FdUrd 61 is restricted to the treatment of liver metastases
caused by colorectal cancer.81 It was first synthesized at Hoffman-La Roche through the
410 reaction (Scheme 44)82,83 of a mercury derivative of 5-FU 81 with a protected 2-deoxy-
D-ribosyl chloride 82 (68–70% yield) followed by separation of a and b-anomers by
crystallization (42.5% of b-isomer) and removal of protecting groups (90%).
The same company obtained FdUrd 61 and its phosphates through a biocatalytic
approach (cells of Streptococcus faecalis).84
Scheme 44
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415 A subsequent approach provided the formation of 20-deoxyribose starting from a pre-
formed b-nucleoside, namely 5-fluorouridine 83. This purpose was achieved by means of
the removal of 20-chlorine 8585 or 20-bromine 8686 in turn obtained by the ring opening of
a O2,2-anhydrouridine 84 (Scheme 45). Use of tributyltin hydride allowed removal of the
20-halogen selectively.
Scheme 45
Synthesis of Antitumor Fluorinated Pyrimidine Nucleosides 27
420 Applying a method developed in 197487 for the synthesis of 20-deoxyuridine from
uridine, floxuridine 61 was obtained in 50% yield from 5-fluorouridine 83. The 20-
hydroxy group was substituted by a bromine atom that was removed by hydrogenation
(Scheme 46).88 A mechanism of the substitution reaction was proposed.
Similar to 5-FU 1 and tegafur 60, the direct fluorination of the peracetylated pre-
425 formed 20-deoxy nucleoside was realized using, as fluorinating agent, trifluoromethyl
hypophosphite.13,15 Perbenzoate 20-deoxyuridine 87 was fluorinated with fluorine in ace-
tic acid (60–90% yield). The benzoyl esters were removed from compound 88 by metha-
nolysis affording floxuridine 61 (60–90% yield)89 (Scheme 47).
Scheme 46
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In a different approach, a study, carried out with the aid of 1H NMR, allowed workers
430 to establish which parameters influence the stereoselectivity of the reaction between the
bis-silyl derivative of 5-FU 47 and 3,5-bis(O-para-chlorobenzoyl)-2-deoxy-a-D-ribofura-
nosyl chloride 89. In the presence of para-nitrophenol the b-anomer of 90 was obtained
stereoselectively in high yields. In the presence of pyridine and para-nitrophenol, the
a-anomer of 90 was formed stereoselectively (Scheme 48).90
435 A biocatalytic approach to floxuridine 61 includes the use either of purified enzymes
or of microorganisms in toto. The regioselective behavior of hydrolytic enzymes towards
the esters of floxuridine was already observed in 1989. A lipase from Pseudomonas fluo-
rescens was able to regioselectively remove the 30-acyl group from the 30,50-diester of
floxuridine 91. The selective removal of the 50-acyl group was achieved by means of sub-
440 tilisin, the protease from Bacillus subtilis (Scheme 49).91
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A synthesis of floxuridine 61 starting from 2-deoxyribose 92 was performed in 2008
through a chemo-enzymatic approach: CAL B, the lipase from Candida antarctica, was
first used to selectively introduce an acetyl group at the 5-position of the carbohydrate
(compound 93) and, in the next step of the synthesis, to selectively remove the same acyl
445 group, under alcoholysis conditions (compound 94). Intermediate 5-phosphate 95 was
used as starting material for the glycosylation reaction catalyzed by a combination of
phosphopentomutase (PPM) and thymidine phosphorylase (TP). PPM catalyzed the trans-
fer of the phosphate group from the 5-position to the 1-position of the furanose, providing
the substrate of TP. Floxuridine 61 was obtained in 60% yield from 2-deoxy-D-ribose-5-
450 phosphate 95 (Scheme 50).92
The use of TP as biocatalyst of the nucleobase exchange reaction, aimed to convert
thymidine 96 to floxuridine 61 (transglycosilation), was also reported. In one case immo-
bilized TP was used (62% yield);93 by using commercially available TP94 a 86% yield
was observed (Scheme 51).
455 Immobilized bacterial cells from E. coli95 or from Lactobacillus animalis 96,97 were
reported to catalyze the transglycosilation reaction of thymidine 96 to floxuridine 61with
62% and 95% yield, respectively.
Similarly to 5-FU 1, floxuridine 61 has a short plasma half-life and causes gastroin-
testinal toxicity. Some esters of floxuridine with long chain aliphatic acids show higher
460 therapeutic indices than floxuridine98 and for this reason the susceptibility of a series of
Scheme 50
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30,50-diesters or 30-and 50-monoesters to porcine liver esterase was investigated. The
obtained results suggested that the higher antitumor activity of longer alkyl chain
diesters of floxuridine was partly due to their slow rate of hydrolysis by non-specific
esterase.
465 Many efforts have been made to develop a variety of prodrugs undergoing hydrolysis
to release floxuridine 61: for example, conjugates with a cyclic peptide with an ester
linker99 or a peptide with a 3-aminoxypropionate-based linker.100 This last prodrug 97
shows a linker that cyclizes readily under physiological conditions and in the interstitial
tissues of solid tumors (Scheme 52).
Scheme 51
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470 Floxuridine binding to antibodies in order to drive the cytotoxic activity101,102 was
also studied; and further photolabile carbonate prodrug 98 was synthesized that, by pho-
tolysis, rapidly released floxuridine 61 (Scheme 53).103
It is known (see Scheme 1) that floxuridine 61 is activated by phosphorylation, catalyzed by
thymidine kinase (TK), to 5-fluorodeoxyuridine monophosphate (FdUMP) 2, the TS-inhibitor.
475 In TK-deficient tumors floxuridine lost its cytostatic potential. Direct administration of phos-
phorylated floxuridine has little therapeutic advantage since the charged monophosphate, under
physiological conditions, shows poor, if any, penetration across the cell membrane. The admin-
istration of lipophilic phosphoramidate 99 can circumvent these problems (Scheme 54).104
According to a recent patent, a floxuridine prodrugwas prepared and a biorthogonal cleav-
480 age (under biocompatible conditions) was suggested (Scheme 55).105 The target of the study
was the development of a prodrug releasing the active drug by means of a reaction susceptible
to occur in a biological environment without interfering with the normal functions of its
Scheme 53
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component. Thus, 3-propargyl-5-fluoruridine 100was synthesized and the free active drugwas
generated using biocompatible palladium catalyst, at 37C and pH 7.4; also the by-product 1-
485 hydroxyacetone 101 is biocompatible. Palladium implants, can, therefore, deprotect the pro-
drug at the disease site, reducing the general systemic concentration of the free drug.
3. Doxifluridine
Doxifluridine (50-deoxy-5-fluorouridine, 50-DFUR) 62 is a prodrug that requires thymidine
phosphorylase (TP) for its one-step conversion to 5-FU 1. Since TP expression is high in the gas-
490 trointestinal tract, doxifluridine therapy resulted in dose-limiting toxicity, such as diarrhea. It is
orally administered for the treatment of breast, stomach, colon cancer and nasopharyngeal
carcinoma.
A large number of 50-deoxy nucleosides have been synthesized taking into account
that several biologically active nucleosides require the presence of a 50-hydroxy group for
495 activation, usually by phosphorylation. Removal of this function provides interesting
compounds for biochemical and biological studies. 50-Deoxy compounds are potentially
interesting medicinal agents, since such molecules cannot be phosphorylated and incorpo-
rated into nucleic acids and thus offer the possibility of reduced toxicity and increased
specificity. The 50-deoxy carbohydrates can be synthesized before the formation of the N-
500 glycosidic bond with the 5-fluoropyrimidine or, alternatively, a preformed nucleoside can
be used as starting material for the 50-modification.
In a 1982 patent,106 the 5-deoxy carbohydrate was prepared, starting from suitably
protected D-ribose 102, through 5-bromo derivative 103 (Scheme 56). Removal of the 5-
bromine atom was achieved by means of a catalytic hydrogenation affording compound
505 104 (90% yield). Deoxy peracetylated sugar 105 was used in the glycosylation reaction
affording diacetate of doxifluridine 106 that was deprotected by means of sodium methyl-
ate (97% yield). The same authors, by this method, prepared also the 50-monodeutero and
the 50,50-dideutero derivatives and the a-anomer of doxifluridine.107
Scheme 55
Synthesis of Antitumor Fluorinated Pyrimidine Nucleosides 33
A modification of the coupling method between the 50-deoxysugar and the 5-fluoro
510 pyrimidine allowed workers to increase the yields and the purity of the final product, at a
temperature below 0C.108
In a 1978 article109 the 50-deoxy group was obtained starting from 5-fluorouridine 83
(Scheme 57), through the simultaneous protection of 20- and 30-hydroxy groups as a cyclic
Scheme 56
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sulphinyl derivative, and the substitution of 50-hydroxy group with a chlorine atom (com-
515 pounds 107), by means of thionyl chloride. The chlorine atom was then removed by reac-
tion with tributyltin hydride.
Protection of the 20- and 30-hydroxy groups of 5-fluorouridine as the isopropylidene
derivative 108, followed by iodination110 afforded suitable 50-iodo intermediate 109 in
order to obtain the 50-deoxy 5-fluoronucleoside 62 (Scheme 58).
520 The same 50-iodo derivative, compound 109, as later reported in an Italian patent,111
was transformed into the 50-deoxy nucleoside by removal of the acetonide, followed by
reaction with tributyltin hydride in toluene (Scheme 59).
Scheme 58
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Another Italian team in 2009112 described a chemo-enzymatic approach to the syn-
thesis of doxifluridine through the regioselective enzymatic hydrolysis of triacetyluridine
525 110 followed by a phosphorylase-catalyzed transglycosylation (Scheme 60). The regiose-
lective hydrolysis of 50-acetate was achieved by means of lipase from Pseudomonas fluo-
rescens in pH 7 buffer; the 50-hydroxy group of compound 111 was transformed into 50-
bromo derivative 112 in two steps. Reduction of 50-bromonucleoside (tributyltin hydride)
and removal of protecting groups afforded 50-deoxy uridine 113, a suitable substrate for a
530 phosphorylase-catalyzed substitution of the nucleobase.
4. Capecitabine
Capecitabine (N4-pentyloxycarbonyl-50-deoxy-5-fluorocytidine, Xeloda) 63, an oral
prodrug of 5-FU, was designed to circumvent the gastrointestinal toxicity of doxifluridine
62 and to generate 5-FU preferentially at the tumor site.113–116 The activation of capecita-
535 bine 63 by transformation into 5-FU required three distinct enzyme-catalyzed steps. After
Scheme 60
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oral administration capecitabine passes the intestine unaltered; in the liver the carbamoyl
moiety is removed by carboxylesterase; the second step is the conversion to 50-deoxy-5-
fluorouridine 62 by cytidine deaminase, an ubiquitous enzyme,117 responsible for the
deamination of nucleosidic analogs, localized in the liver and in various tumor types.
540 Finally, 50-deoxy-5-fluorouridine 62 can be converted to 5-FU in the tumors by thymidine
phosphorylase,118 an enzyme that leads to the preferential generation of 5-FU in tumors
as a result of its overexpression in malignant tissue (Scheme 61).
Capecitabine 63 is approved in the European Union, USA, Canada and Australia for
the treatment of advanced or metastatic colorectal carcinoma.119–122 In combination with
545 other antineoplastic agents, it can be utilized also in metastatic breast cancer.123–127 Syn-
theses of capecitabine were reviewed in 2010 in a book chapter.128
In themolecule of capecitabine 63 threemoieties can be recognized: the 50-deoxy-D-ribose,
the 5-fluoropyrimidine and the pentyloxycarbonyl group. Similarly to the doxifluridine synthesis,
theN-glycosylation can be carried out starting fromD-ribose, postponing the formation of the 50-
550 deoxy group to a subsequent step, or from the previously prepared 50-deoxy-D-ribose. Also the
N4-carbamoyl function can be introduced in the course of different steps of the synthesis.
Several syntheses start from triacetyl-5-deoxy-D-ribose 105 that, in turn, can be prepared
from methyl 2,3-O-isopropylidene-D-ribofuranoside 115 through the formation of 5-O-mesyl
derivative 116, the substitution of the mesylate group by an iodine atom (compound 117) and
555 the reductive removal of the latter. Deprotection and acetylation followed by crystallization
afforded the b-anomer of 1,2,3-O-triacetyl-5-deoxy-D-ribose 105 (Scheme 62).129
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Peracetylated 5-deoxy-D-ribofuranoside 105 was also prepared in a different way,
starting from 2,3-O-isopropylidene-D-ribofuranoside 115, through the 5-bromo-deriva-
tive and used in the N-glycosylation step, as described in the case of doxifluridine synthe-
560 sis (see Scheme 56).106
In more recent work130 the removal of the 5-hydroxy group was realized through the
reduction of suitably protected 5-O-tosyl ester 119 by means of lithium aluminum hydride
(Scheme 63); after deprotection and acetylation the 1,2,3-O-triacetyl-5-deoxy-D-ribose
105 was obtained as a 1:3 a/b anomeric mixture. A ratio more favorable to the b-anomer
565 was observed131 by modification of the reaction conditions of 5-deoxy-D-ribose acetyla-
tion; indeed, using triethylamine in dichloromethane solution as the base, instead of pyri-
dine, the acetylation afforded a 1:13.8 a/b anomeric mixture (Scheme 63). Pure b-isomer
105 was recovered in 80% overall yield by crystallization.
A different reducing agent for 119 (sodium borohydride in dimethylsulfoxide)132
570 allowed the synthesis of 1,2,3-O-triacetyl-5-deoxy-D-ribose 105 in 56% overall yield
from D-ribose (Scheme 64). Pure b-anomer was recovered after crystallization (60%).
Scheme 63
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An improvement of this method was described in a 2013 Indian patent:133 5-O-Tosyl
derivative 119 was obtained, avoiding the use of pyridine, by reaction of 1-O-methyl-2,3-
O-isopropylidene-D-ribose 115 with para-toluensulfonyl chloride and sodium hydroxide
575 in toluene, in the presence of tetrabutyl ammonium bromide (Scheme 65).
In 2000,134 1,2,3-O-triacetyl-5-deoxy-D-ribose 105 was used as starting material for
the glycosylation of the silyl derivative of 5-fluorocytosine 120 in the presence of stannic
tetrachloride or trimethylsilyl iodide. Reaction with n-pentyl chloroformate and removal
of protecting groups afforded the desired capecitabine 63 (Scheme 66). Instead of stannic
580 tetrachloride, triflic acid can be used as acid catalyst.135
The N-glycosylation was also carried out without silylating agent, in a “one-pot” pro-
cedure that afforded capecitabine 63 in 60% yield (Scheme 67).136
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Other syntheses were designed starting from a differently protected 5-deoxy-D-
ribose. For example 5-deoxy-D-ribose 118 was transformed into corresponding ace-
585 tonide 121 by reaction with 2,2-dimethoxypropane in the presence of para-toluen-
sulfonic acid, in dimethylformamide as solvent. Acetylation of the 1-hydroxy
group afforded the suitable intermediate, compound 122, for the glycosylation of
N4-pentyloxycarbonyl-5-fluorocytosine 123 under the usual conditions. Acidic
treatment (Amberlyst 15) of obtained 124 afforded final capecitabine 63
590 (Scheme 68).137
The 1,2,3-hydroxy groups of 5-deoxy-D-ribose 118 were also protected as methyl
carbonates (compound 125) providing a 1:2.7 a/b anomeric mixture (63%) that was
directly used in the glycosylation step. 20,30-Protected-50-deoxy-5-fluorocytidine 126 was
recovered, after precipitation of undesired by-products, and submitted to the reaction
595 with pentyl chloroformate; removal of 20,30-carbonates under basic conditions and crys-
tallization afforded capecitabine 63 (Scheme 69).138
A mixture of a- and b-anomers of 1,2,3-tri-O-acetyl-D-5-deoxy-ribose 105, was also
used in the glycosylation of N4-pentyloxycarbonyl-5-fluorocytosine 123, that is on the 5-
fluorocytosine already derivatized on the 4-NH2 (Scheme 70).
139
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600 The preparation of the N4-pentyloxycarbonyl derivative seems to be the crucial step
of this synthesis.
The introduction of the carbamoyl function, according to two Hoffman-La Roche
patents, published in 1995,140,141 was postponed to the last step of the synthesis. In one
case 141 the N4-functionalization was realized directly on 50-deoxy-5-fluorocytidine 114
605 affording in 92% yield 50-deoxy-20,30-di-O-pentyloxycarbonyl-5-fluoro-N4-pentyloxycar-
bonylcytidine 128. The 20,30-carbonates were removed with aqueous sodium hydroxide in
methanol (Scheme 71).
An improvement of the preparation of the N4-pentyloxycarbonyl derivative was
obtained by Teva by modifying the reaction conditions:142 choosing 2-methyltetrahydro-
610 furan as solvent, the pyridine amount was significantly reduced (1.7 eq), avoiding its
removal by evaporation in the course of work-up. After removal of acetates from com-
pound 129 pure capecitabine 63 in 86% yield was obtained (Scheme 72).
Attempts to introduce the pentyloxycarbonyl group directly on an unprotected 50-
deoxy-fluorocytidine led to the development of new reagents, different from the usual
615 pentylchloroformate, able to selectively functionalize the N-4. With this purpose in mind,
starting from N-hydroxysuccinimide143, a new pentylcarbonate 130 was recently prepared
in 98% yield that selectively functionalized the unprotected 50-deoxy-fluorocytidine at N-
4, affording capecitabine 63 in 44% yield (Scheme 73).
Scheme 71
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With the same aim, some pentyloxycarbonylation reagents like hydroxybenzotria-
620 zole-131 and pentafluorophenoxyderivative, 132 were prepared144 and used to selectively
form capecitabine 63 from 50-deoxy-fluorocytidine 114, in 66 and 67% yield, respectively
(Scheme 74).
The same authors also published a method145 for the preparation of N-functionalized
cytidine that, using pentylchloroformate, required the protection of 20and 30-hydroxy
625 groups, obtained through the formation, by reaction with thionyl chloride, of cyclic sul-
finyl ester 133, easily purified by crystallization (85% yield). After the N4-functionaliza-
tion (85%), the sulfinyl ester of compound 134 was removed by treatment with 1M
sodium hydroxide and methanol affording capecitabine 63 (82%) (Scheme 75).
Scheme 73
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Recently a continuous synthesis146 (Scheme 76) was reported: the synthetic pathway starts
630 from 1,2,3-O-triacetyl-5-deoxy-D-ribose 105 and the glycosylation is catalyzed by a Brønsted
acid chosen from among the piridinium triflates. Capecitabine 63 is recovered at the end of the
one-flow,multistep synthesis in 72% yield. Thismethodwas applied also to other 50-deoxyribo-
nucleosides as the previously reported doxifluridine 62 (89%) and galocitabine 135 (see below).
Since capecitabine 63 is an active pharmaceutical ingredient the identification and
635 the determination of its impurities, as well as the optimization of HPLC methods are very
important aspects to be considered together with the synthetic procedures. Some HPLC
methods142,147 and some purification processes utilized for the preparation of substan-
tially pure capecitabine were reported.148,149 In one of these patents149 is mentioned the
possibility of removing the 20,30-O-acetyl groups by means of a hydrolytic enzyme, an
640 unspecified lipase. On the other hand the chemo-enzymatic approach is very attractive for
a polyfunctional compound such as capecitabine 63, considering the capability of
enzymes to catalyze selective transformations.
The enzyme-catalyzed regioselective hydrolytic removal of 50-acetate from nucleo-
side triacetate 110 (See Scheme 60)112 allowed workers to obtain the 50-hydroxy-20,30di-
645 O-acetyl derivative 111 suitable for the reductive removal of the 50-hydroxy group, neces-
sary to obtain the 50-deoxy nucleoside. In a previous patent150 the same research team
reported the results about the selective deprotection of hydroxy groups of nucleosides pol-
yesters by means of immobilized lipases; moreover, the topic of regioselective lipase cat-
alyzed transformations of nucleosides is treated exhaustively. In 2008,151 they applied the
650 enzymatic regioselective hydrolysis of 50-O-acetyl group to the 20,30,50-tri-O-acetyl-5-flu-
orocytidine 136 and to N4-pentyloxycarbonyl-5-fluoro-20,30,50-tri-O-acetyl cytidine 137
(Scheme 77) obtaining advanced intermediates of capecitabine synthesis. High yields
were obtained in both 4-NH2 compound 136 (80–97%, immobilized Candida rugosa
lipase as enzyme) and N4-derivativative 137. On this last substrate the highest yield
655 (92%) was obtained by using the immobilized protease N from Bacillus subtilis.
Scheme 76
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The same regioselective hydrolysis was also studied comparing immobilized
recombinant or commercially available lipases from Candida rugosa.152
More recently,153 the chemo-enzymatic approach to a capecitabine intermediate,
compound 140, quite similar to that prepared by Cook and co-workers in 1979110
660 (Scheme 78) for doxifluridine 62 synthesis, was studied.
20,30,50-Tri-O-acetyl-5-fluoro-N4-pentyloxycarbonyl-cytidine 137, substrate of the
enzymatic reaction, was prepared as depicted in enzymes, the best results being observed
in the case of a cross linked aggregate preparation of the protease from Bacillus licheni-
formis (subtilisin), the Alcalase-CLEA: at 96% conversion the 50-acetate was removed
665 almost exclusively (91%). In order to transform advanced intermediate 139 into the final
capecitabine a careful study about the more suitable 50-functional group and reducing
agent was necessary. The 50-deoxynucleoside was obtained starting from 50-
Scheme 77
Scheme 78
Synthesis of Antitumor Fluorinated Pyrimidine Nucleosides 45
iododerivative 140 by reaction with tributyltin hydride, followed by deprotection of the
20,30-O-diacetyl groups (Scheme 79). The CLEA preparation increases the stability of the
670 enzyme in alcoholic solutions and allows an easier work-up. The work includes the 1H
and 13C NMR analyses of the nucleosidic intermediates and of the final capecitabine.
Scheme 79, starting from commercially available intermediates. Triacetate 137 was
treated, under alcoholysis conditions, with some hydrolytic
Finally, another chemo-enzymatic approach was described in 2015.154 In this
675 case, similarly to an already described doxifluridine 62 synthesis112 the biocatalyzed
reaction was a transglycosylation reaction of 50-deoxyuridine 113 and the preformed
nucleobase of capecitabine, namely N4-pentyloxycarbonyl-5-fluorocytosine 123; the
employed enzyme was a pyrimidine nucleoside phosphorylase (Scheme 80).
After the introduction in therapy of capecitabine 63, several analogues were synthe-
680 sized and submitted to biological tests with the aim of enhancing its efficacy. Mainly, the
modifications were carried out on the N-4 position where different groups, such as for
instance BOC155, were introduced instead of the pentylcarbamate.
The substitution of an N-4 bonded group can lead to a prodrug that, in hypoxic
environments typical of solid tumors, can be reduced by one-electron processes that are
685 inhibited in the normoxic environment of normal tissues. Radiolysis can activate a
Scheme 79
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prodrug to release the active drug after one-electron reduction. An example of a suitable
prodrug for radiolysis is N4-nitrothienylderivative 141 described in a 2006 patent
(Scheme 81).156
Some 20,30-O-cyclic carbonates 142 modified at N-4 showed potent antitumor activ-
690 ity against a leukemia cell line.157 Their synthesis is reported in Scheme 82.
Scheme 81
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5. Galocitabine
Galocitabine (50-deoxy-5-fluoro-N4-(3,4,5-trimethoxybenzoyl)cytidine), (Ro 09–1390) 135,
can be considered as a capecitabine derivative with a different N4-substituent or as a doxi-
fluridine prodrug, since at pH 2.1 it rapidly decomposes affording the latter compound.158
695 Galocitabine was synthesized from 20,30-diacetate-50-deoxy-5-fluorocytosine 129 in 1995159
according to Scheme 83. Instead of trimethoxybenzoyl chloride a different derivative of tri-
methoxybenzoic acid can be used,144 for example the pentafluorophenoxy ester.
Scheme 82
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The 20,30-O-cyclic sulfinyl ester145 of 50-deoxy-5-fluorocytidine 114 was an alterna-
tive protecting group, utilized during the introduction of N4-acyl group.
700 The continuous flow synthesis, like in the case of capecitabine 63, was also applied to
the preparation of galocitabine 135 (89%).146
6. 1-Ethoxymethyl-5-Fluorouracil and Emitefur
1-Ethoxymethyl-5-fluorouracyl 143 and emitefur 144 (Scheme 84) have in common the
same N1-substitution, namely an ethoxymethyl moiety, which is an acyclic ether, instead
705 of the tetrahydrofuran ring present in tegafur 60. Moreover, emitefur (more commonly
called BOF-A2) 144 is also functionalized on N-3. Both were designed to explore 5-fluo-
ropyrimidine analogues of nucleosides endowed with improved antitumor activity.
1-Ethoxymethyl-5-fluorouracyl 143 was synthesized in 1978 in very poor yield (4%)
by reaction of ethoxychloromethane with 5-FU 1160 or by reaction of the silylderivative
710 of 5-FU 47 with diethoxymethane and sodium iodide (44% yield)161 or stannic chloride
(14% yield),162 as depicted in Scheme 85.
Scheme 84
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Starting from 1-ethoxymethyl-5-fluorouracil 143 emitefur 144 was prepared in 25%
yield (Scheme 86)163,164 by reaction with the isophthaloyl chloride 145 followed by reaction
with 6-benzoyloxy-3-cyano-2-pyridone 146. Emitefur 144 is degraded in vivo into 1-ethoxy-
715 methyl-5-fluorouracyl 143, a prodrug of 5-FU, and 3-cyano-2,6-dihydroxypyridine (CNDP)
147, a competitive inhibitor of DPD, the enzyme responsible for rapid degradation of 5-FU 1.5
7. Carmofur
Carmofur 148 is the international non-proprietary name of 1-hexylcarbamoyl-5-fluoro-
uracil (HCFU), an antineoplastic agent orally administered in resected colorectal cancer
720 patients. It has some anticancer activity of its own and it is ultimately transformed in vivo
to 5-FU 1.165 It was prepared165 starting from 5-FU 1 by reaction with hexyl isocyanate
in pyridine or in dimethylacetamide solution, or by reaction with phosgene followed by
treatment with 1-hexylamine (Scheme 87). The hexyl isocyanate was, in turn, prepared
starting from heptanoyl chloride by reaction with sodium azide,165 or by treatment of 1-
725 hexylamine with trichloromethyl chloroformate, followed by distillation.166
In a polar solvent, like dimethylsulfoxide, carmofur 148 exists as two mixed structures
(presumably a hydrogen-bonded structure and a non-hydrogen-bonded structure) at room
temperature, as demonstrated by 1H NMR analyses166 in DMSO-d6 at room temperature and
at 80C or in CDCl3. Deuterated derivatives of carmofur bearing deuterium atoms on the
730 hexyl chain were prepared in order to evaluate the isotopic effect on the metabolism rate.165
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8. Related Non-Clinical Fluoropyrimidine Nucleosides
New syntheses of fluoropyrimidines nucleosides are usually aimed at the preparation of
new potential antitumor, antiviral or antibacterial compounds and their destiny depends
on the results of clinical investigations. The fluorination in most cases takes place at the
735 5-position, namely the position involved in the thymidine biosynthesis. In the previously
examined compounds the fluorine atom is directly linked to C-5 of heteroaromatic ring.
In the case of 5-trifluorothymidine (TFT) 149 a trifluoromethyl group instead of the 5-
methyl group is present.
Scheme 87
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TFT 149 was synthesized in 1964 by Heidelberger167 according to Scheme 88, but its
740 development as antineoplastic agent was early hampered by its short half-life (12 min).168
The renewed recent interest for TFT 149, prompted the synthesis of a convenient pro-
drug. In a 2016 patent 169 the silylation of 30 and 50-hydroxy group of TFT was realized in
order to prolong the TFT 149 circulatory half-life. Two methods of silylation affording
compound 150 (Scheme 89) were described.
745 III. Pyrimidine Nucleosides Fluorinated at the Sugar Moiety
Fluorine atom introduction at nucleosides can occur not only at the pyrimidine moiety but
also at the glycone moiety, modifying the biological activity to an equally significant
extent, leading to antiviral or antitumoral molecules. The sugar can be fluorinated at
20,30,4,50-positions or can bear an exocyclic fluorocarbon substituent. Considering that
750 some reviews170–173 already cover the topic of nucleosides fluorinated at the sugar moi-
ety, we focused on an antitumor pyrimidine nucleosides difluorinated at the 20-position,
namely gemcitabine. The presence of fluorine at the 20-position can provide acidic and
enzymatic stabilities to the glycosidic bond174 and the gem-difluoromethylene group is an
isopolar and isosteric substituent for oxygen.175 Extensive studies about the 20-position
755 modification with atoms or groups other than hydrogen or hydroxy (for example Cl,176,
N3,
177 Se,178 CH3,
179,180) have been performed, since the presence of a hydroxy or a
hydrogen distinguishes nucleosides as components of RNA or DNA.
1. Gemcitabine
Gemcitabine 151 hydrochloride (20,20-difluoro-20-deoxycytidine hydrochloride) is cur-
760 rently produced and marketed as Gemzar for the treatment of various cancers such as
pancreatic, breast, non-small cell lung and ovarian cancers. It is administered by intrave-
nous infusion, the oral use of gemcitabine being limited by poor bioavailability.
Gemcitabine is intracellularly converted by deoxycytidine kinase into its therapeutically
active metabolites, the 50-diphosphate 152 and the 50-triphosphate derivatives 153
765 (Scheme 90).
50-Diphosphate 152 inhibits the ribonucleotide nuclease, the enzyme responsible for
regulating the total rate of DNA synthesis, while 50-triphosphate 153 can become incorpo-
rated into the DNA and inhibits the nuclear replication. The 50-position is directly
involved in the action of gemcitabine 151, while the 4-NH2 group plays a role in the
Scheme 89
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770 enzyme-substrate recognition through the formation of hydrogen bonding interactions
with the kinase; the removal of the amino group by the liver enzyme cytidine deami-
nase117 leads to the inactive metabolite 20,20-difluorouridine.
The preparation of the 20,20-difluorosugar is the main target in gemcitabine 151 syn-
thesis and many different approaches have been proposed (some of that described in a
775 minireview181) since the first synthesis reported by Hertel in 1988.182
The starting material for this synthesis (Scheme 91) was protected (R)-glyceral-
dehyde 154 prepared from D-mannitol; its reaction with ethyl bromodifluoroacetate
led to a diastereomeric mixture of (3R)- and (3S)-propionate (3R/3S 3:1) derivatives
155 that were separated by silica gel column chromatography. The (3R)-isomer,
780 under acidic conditions afforded lactone 156 that, after protection of 3- and 5-
hydroxy groups (compound 157), was reduced with diisobutylaluminum hydride to a
mixture of a- and b-anomers (158); the anomeric mixture was transformed into the
corresponding 1-O-mesylate (compound 159) necessary for the substitution by the
silyl derivative of cytidine. The formation of the N-glycosidic bond was the crucial
785 step of the synthesis since the required b-anomer of 151 was the minor product
(10%). The undesired a-anomer was obtained in 40% yield, after removal of the pro-
tecting group and separation by reverse phase column chromatography.
An improvement to this synthesis was achieved by Chou and co-workers,183
some years later, through the selective crystallization of the diastereomeric mixture
790 of 3,5-di-O-benzoyl-difluororibono-lactone 161 obtained by esterification of 30-ben-
zoate 160 (Scheme 92). The choice of benzoyl as protecting group of 3- and 5-
hydroxy groups allowed selective crystallization of the desired erythro-isomer.
Reduction of the 1-carbonyl group afforded a mixture of a- and b-anomers 161
that was transformed into the corresponding mesylates 162. The glycosylation reac-
795 tion afforded a 1:1 a/b anomeric mixture of nucleosides 163 instead of the 4:1
mixture observed by Hertel which used tert-butyldimethylsilyl ether as protecting
group.
Starting from protected (R)-glyceraldehyde 154 many modifications, aimed to
improve the yield and the purity of the final b-anomer, were proposed relating to the
Scheme 90
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800 use of different reducing agents of the lactone, to the introduction of alternative pro-
tecting groups, to the transformation of 1-hydroxy into a different leaving group
and, finally, to the purification process of the obtained gemcitabine 151. More than
ten patents have been published in 2005–2015 about this topic. For example, an
Indian team184,185 was able to obtain 3,5-di-O-benzoyl-2,2-difluoro-lactone with a
805 high purity (99.8% erythro-isomer) by treatment of the diastereomeric mixtures of
lactones 164, containing also the corresponding hydroxyacid 165, with para-toluen-
sulfonic acid in toluene, at reflux, removing the water by means of the Dean-Stark
apparatus, followed by crystallization (Scheme 93). Reduction with Vitride (sodium
bis(2-methoxy)aluminum hydride, also known as Red-Al or SMEAH) followed by
810 treatment with mesyl chloride afforded usual intermediate 162 for the accomplish-
ment of the synthesis. The gemcitabine hydrochloride showed a 95% diastereomeric
purity that was increased to 99.9% by means of crystallization by water/acetone or
water/2-propanol.
Another approach186 made use of DIBAL as reducing agent of protected lactone 166
815 and mesylate as leaving group in compound 167, postponing all purification processes
until the end of the synthesis. By this method, 92.6% pure gemcitabine was obtained after
Scheme 91
54 Ferraboschi, Ciceri, and Grisenti
column chromatography. The final crystallization of gemcitabine hydrochloride from
water/acetone afforded 99.6% pure gemcitabine hydrochloride (Scheme 94).
The choice of a suitable protecting group187 for the 3- and 5-hydroxys (benzoyl
820 substituted with an electron withdrawing group), with the aim to obtain solid compounds,
allowed preparation of the pure erythro-lactone 168 by crystallization from ethyl acetate/
hexane. The synthesis was then finished in the usual way; the precipitation of gemcitabine
hydrochloride afforded 99.9% pure product (Scheme 95).
Tri-tert-butoxyaluminum hydride was used in the course of the reduction of the lactone
825 protected as 3,5-di-O-(3-fluorobenzoyl) ester187 or 3,5-di-O-(4-phenyl)benzoyl ester.188 By
means of Red-Al was instead obtained the lactol, protected at the hydroxy groups as tert-
butyldimethylsilyl ethers189 or benzoates,190,191 or naphthoyl esters,192 or as 3-O-benzoate
and 5-carbamate.193 In this last case, the trichloroacetimidate was chosen as the leaving
group. If the same leaving group was introduced and the obtained trichloracetimidate directly
830 submitted to the reaction with protected cytidine, in a “one-pot” process,190 the protected
Scheme 92
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nucleoside was obtained in high yield (89%); gemcitabine hydrochloride was obtained
(99.94% b-anomer) in 30% yield after deprotection and purification process.
The use of the cinnamoyl ester as protecting group of 3- and 5- hydroxyl allowed the
selective precipitation of an anomer at different steps of the synthesis.194,195
835 In order to avoid the energy waste required to maintain the low temperatures
(between ¡80 and ¡60C) during the reduction of the 1-carbonyl group with DIBAL, in
a 2010 patent the use of calcium borohydride in tetrahydrofuran (90% yield) or sodium
borohydride in ethyl acetate (88% yield) was proposed.196
In order to increase the b/a anomer ratio, 1-iodido-2,2-difluoro derivative 169,
840 as substrate of the N-glycosylation, was prepared through two alternative ways:
directly from 1-hydroxy 170 by reaction with iodine and triphenylphosphine in
dichloromethane, or through its mesylate, with sodium iodide in acetone. The addi-
tion of a silver salt to the glycosylation reaction mixture led to the formation of oxo-
nium intermediate, 171 that underwent the attack of nucleobase from the top of the
845 molecule, favoring the formation of the b-anomer (a/b 1:5.6).197 In a more recent
patent198 the authors reported that even more favorable ratios can be obtained adding
Scheme 95
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an oxidizer; for example, a 1:18 a/b anomer ratio was observed using (NH4)2S2O8 in
acetonitrile. (Scheme 96).
The presence of a bulky protecting group (para-phenylbenzoate)199,200 of the 3-
850 hydroxy group allowed workers to obtain a solid 1-phosphate, compound 172 show-
ing a 1:10.8 a/b ratio, that by a simple crystallization afforded in 77% yield the
b-anomer (98.24% pure). The b-phosphate was easily converted into the correspond-
ing a-bromo derivative 173, which is a suitable precursor, after crystallization, of
the N-glycosylated product with the desired b-stereochemistry. In order to avoid pos-
855 sible anomerization of a-bromo sugar 173 the trimethylsilyl bromide, generated in
Scheme 96
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the course of substitution with the protected nucleobase, was removed by distillation
using heptane as carrier. By this method, glycosylation occurred in high yields
(92%) giving compound 174 showing a 1:5.5 a/b ratio. Pure gemcitabine 151 was
obtained, after removal of protecting groups and crystallization in 65% yield from
860 a-bromo sugar 173 (Scheme 97).
Scheme 97
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According to a different approach, instead of the usual protected (R)-glyceraldehyde
154, 1,6-anhydro-b-D-glucose 175, prepared by thermal degradation of starch, was used
as starting material.201
2,4-Trimethylsilyl ether 176was oxidized to 3-keto derivative 177 by means of Dess-Mar-
865 tin reagent. After removal of the silyl ether the 2- and 4-hydroxy groups were transformed into
corresponding methyl ethers 178 (96% yield) and the 3-ketoderivative was converted into gem-
difluoro derivative 179 by reaction with diethylaminosulfuryl trifluoride (DAST) and N,N-
dimethylpropylene urea-hydrogen fluoride (DMPU-HF) (90% yield). Opening the anhydro ring
under acidic conditions (compound 180) and oxidation with sodium periodate afforded 2-
870 deoxy-2,2-difluoro-D-ribose 181 in 68% yield. The synthesis was accomplished as reported in
Scheme 98. 1,3,5-Tri-O-acetyl-D-ribose difluoroderivative 182was condensed with the N1-cis-
(2-cyanovinyl)-N,N-bistrimethylsilyl urea and the obtained intermediate was cyclized under
strong alkaline conditions to the final b-nucleoside in 11% yield, after column chromatography.
The overall yield from 1,6-anhydro-b-D-glucose 175 was 4.4%, confirming the difficulties
875 encountered in other synthetic approaches, deriving from the presence of two stereogenic cen-
ters, in the 1- and 3-positions, generated or modified in the course of the synthesis.
The direct fluorination of a preformed nucleoside can overcome the formation of the
erythro and threo-diastereoisomers encountered starting from (R)-glyceraldehyde 154; in
addition, the N-glycosylation with a non-fluorinated sugar can afford a more favorable
880 a/b anomers ratio. To this end, a suitably protected 20-ketonucleoside 183 was prepared
starting from the commercially available cytidine and submitted to the reaction with
Scheme 98
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DAST in presence of pyridine-hydrogen fluoride (Scheme 99).202 N4, 30,50-Tri-(ortho-
toluyl)-20-ketocytidine 183 was prepared in 53% overall yield from cytidine. Reaction
with the fluorinating agent afforded protected difluoronucleoside 184 (80% from HPLC
885 and NMR) that was converted into gemcitabine 151 by removal of protecting groups.
In another example 2-deoxy-D-ribonolactone 185 was chosen as the substrate of the
fluorination, which was carried out in two steps with N-fluorodibenzenesulfonimide
(NFSi) in presence of lithium bis(trimethylsilyl)amide (LiHMDS) (Scheme 100).203 Pro-
tected gem-difluororibonolactone 186, obtained in 47% yield from 2-deoxy-D-ribonolac-
890 tone 185, was then transformed into gemcitabine 151 as depicted in Scheme 100.
In 2014, a team of Merck researchers published the synthesis of 2-deoxy-2,2-difluoro-D-
ribose according to their “de novo” approach (Scheme 101).204 Optically active aldehyde 187
(83% ee) prepared through an enantioselective method, developed by the authors, was coupled
with isopropyl bromodifluoroacetate under Reformatsky conditions: the suitably functionalized
895 pentanoate was obtained as a mixture of diastereoisomers 188. Purification by flash chromatog-
raphy provided the required diastereoisomer in 59% yield. Removal of the 2,2,6,6-tetramethyl-
piperidinyl group (TMP) and concomitant cyclization afforded the difluorolactone 189
precursor of the ribose ring. Gemcitabine synthesis was then carried out through 1-iodine deriva-
tive 190, in the presence of persulfate, as previously reported.197,198 (see Scheme 96). At the end
900 of the synthetic sequence gemcitabine was isolated in 23% overall yield, from optically active
aldehyde 187, and a 1:4a/b-anomers ratio. This synthesis offers a promising approach to gemci-
tabine preparation; indeed the final purification could be carried out according to published
methods.
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Beside the synthetic work, there are some publications dedicated exclusively to the
905 purification of gemcitabine base or hydrochloride. For example 99.8% pure gemcitabine
hydrochloride was obtained by fractional crystallization at acidic pH ( 0.5).205
2. Gemcitabine Derivatives
Gemcitabine chemotherapeutic efficacy is limited by its high toxicity to normal cells and short
plasma half-life (9–13 min for human plasma) depending on the rapid deamination by cytidine
910 deaminase in the liver, kidneys and plasma to less cytotoxic metabolites. Various prodrug strat-
egies have been developed to overcome these adverse aspects and to allow for oral delivery.
Protection of the 4-amino group, for example as the amide, can facilitate a slower
release of gemcitabine, increasing the bioavailability and uptake and providing resistance
to enzymatic deamination. A series of 4-N-alkyl and 4-N-alkanoyl compounds were pre-
915 pared in 2014206 and their activity evaluated. N-alkanoyl gemcitabine derivatives 191
showed potent cytostatic activity in the nanomolar range, whereas N-alkyl derivatives
192 required micromolar range. The N-alkanoyl derivatives 191 were prepared in 40–
66% yield by reacting gemcitabine with a carboxylic acid in dimethylsulfoxide, in pres-
ence of N-methylmorpholine, 1-hydroxybenzotriazole and (N-dimethylaminopropyl)-N1-
920 ethyl-carbodiimide (Scheme 102). The N4-alkyl derivatives 192 were prepared from pro-
tected gemcitabine 193 through its N4-tosylate by reaction with an amine.
N4-(2-Propyl-1-oxopentyl) derivative 194 was prepared in 2006,207 by Eli Lilly
(Scheme 103), designed to be resistant to deamination by hydrolysis under acidic condi-
tions similar to those found in the digestive system but able to release gemcitabine
925 upon action by carboxylesterase.
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N4-Benzoyl derivative 195 was prepared as depicted as shown in Scheme 104 and
included into oligonucleotides aimed to preferentially kill cancerous cells over non-cancer-
ous cells.208 Some oligonucleotides containing gemcitabine derivatives were shown to be
more effective in killing cancerous cells at equivalent dosages of gemcitabine itself.
930 As in the case of capecitabine156 the hypoxic conditions of tumor cells can selec-
tively activate a prodrug, mediating the fragmentation of a masked cytotoxic compound
into the active cytotoxic agent; the masked cytotoxic agent can be N4-carbamate 196156
(Scheme 105) or a 50-ester with lipoic acid derivative 197209 (Scheme 106) that plays the
role of the redox-modulating agent.
935 In a 2013 article the conjugation of gemcitabine with coumarin derivative 198 and
biotin derivative 199 was described:210 the molecule contains the cleavable disulfide
group of biotin, a molecule taken up preferentially by cancer cells, and a fluorescent moi-
ety to enable real-time monitoring of the drug delivery. The synthesis of conjugate 200
and the proposed mechanism of action under physiological conditions, involving GSH,
940 the most abundant thiol in the cells, are depicted in Scheme 107.
Scheme 101
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Besides conjugation with polymeric materials,211,212 the preparation of N4-deriva-
tives with lipoaminoacid residues, suitable for penetration through biological membranes
and barriers, was also reported.213 Lipoaminoacids are aminoacids bearing an alkyl chain
in the 2-position. They impart to the molecule to which they are conjugated amphiphilic
945 properties. Lipoaminoacid derivatives 201, prepared in 69% yield from gemcitabine
hydrochloride (Scheme 108), in vitro results were encouraging of the study of the loading
of these derivatives in liposomes and in other lipid based drug carriers.
Controlled drug delivery from chiral molecules is the aim of a study about the possi-
bility of incorporating gemcitabine into the enantiomers of bis(diamido)-bridged basket
950 resorcin[4]arene 202,214 in the gaseous phase (Scheme 109). The diastereomeric com-
plexes among the macrocycle, gemcitabine and a chiral amine behave as supramolecular
devices which, depending on the configuration of macrocycle and amine, can or cannot
release the nucleoside. Complexation phenomena were investigated215 by NMR methods
and molecular modeling, allowing the identification of two different interaction sites of
955 the guest in the resorcin[4]arene host. Different behaviors of resorcin[4]arene complexes
with 20-deoxycytidine, its 20-epimer cytarabine and gemcitabine were observed. Accord-
ing to the authors, the assessment of the factors regulating the formations of these com-
plexes offers the possibility to modulate the drug/receptor interactions, through the
electronic properties of 20-substituents on the nucleoside furanose ring.
960 The bioorthogonal approach, already described in the case of floxuridine,105 was also
applied by the same authors to the preparation of gemcitabine prodrugs.216 Between the two
masking possibilities, 50-O-carbonate or N4-carbamate, the latter was chosen due to its higher
Scheme 104
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stability to enzymatic metabolism. Starting from gemcitabine 151, propargyloxycarbonyl
derivative 203was prepared (Scheme 110), and treated with a Pd0-functionalized resin under
965 biocompatible conditions (buffer pH 7.4, 37C), in order to remove the carbamate, and, then,
placed in cell culture. In both cases the formation of free gemcitabine was monitored. DNA
damage observed in pancreatic cancer cell cultures treated with N4-functionalized gemcita-
bine and Pd0-resin confirmed the bioorthogonal generation of free gemcitabine 151.
3. Related Non-Clinical Pyrimidine Nucleosides Fluorinated at the Sugar Moiety
970 20,20-Difluorinated azacytidine 204 and 20,20-difluorodeoxyribose-trifluorothymidine 205
were recently169 prepared starting from suitably protected 1-bromo-20,20-difluorosugar,
compound 206, in turn prepared as depicted in Scheme 111 and silylated (see Scheme 88)
in order to obtain new fluoronucleosides.
Compound 204 is noteworthy for the presence of a nitrogen atom at the 5-position,
975 instead of a carbon, in addition to other modifications. Future studies will establish the
clinical usefulness of these modifications.
In 2015217 two 20-fluorotricyclo-DNA nucleosides 207 and 208 were synthesized.
The introduction of fluorine on methylglycoside 209 was achieved through the electro-
philic addition of Selectfluor to the 1,2-double bond of 210 and an approximately equimo-
980 lar mixture of 2-ribo 211 and 2-arabino 212 fluoro sugars was obtained as established by
1H NMR NOE studies (Scheme 112).
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The highly selective N-glycosilation of 2-ribosugar 211, obtained after column chro-
matography, afforded thymine 20-fluoro nucleoside 207 showing a 1:12 a/b anomeric
ratio (Scheme 113).
985 The same intermediate 213 was converted into nucleoside 208 bearing the 5-methyl-
citosine as nucleobase according to Scheme 114.
Compounds 207 and 208 represent two novel fluorinated nucleoside analogues which
in the future will be incorporated into oligonucleotide backbone structures.
IV. Radiolabeled Fluoropyrimidine Nucleosides as PET Tracers
990 Radiolabeled antitumor agents may provide useful information about their metabolism and
pharmacokinetics, in vivo, using functional imaging modalities such as Positron Emission
Tomography (PET). Indeed, due to its good spatial resolution, PET allows workers to map
the distribution of the radiotracers and their biological targets; moreover, depending on the
selected molecular structure, PET is a powerful tool to accurately measure metabolic factors
995 and/or biochemical and physiological parameters. In the last decades, PET has found its
major applications in oncology, where the preparation of molecules labeled with positron
emitting radionuclides, and their subsequent use with human subjects provides useful diag-
nostic information. It even allows clinicians to directly affect therapeutic strategies. Based
on the detection of high energy gamma photons generated by the annihilation of the posi-
1000 tron-electron pairs, PET is a highly sensitive technique, and radiolabeled tracers in nano to
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picomolar concentrations (non-pharmacological concentrations) may be used, thus minimiz-
ing their potential toxicity. The most useful PET radionuclides are the short half-life 11C (t1/2
D 20.4 min) and 18F (t1/2 D 109.6 min). The first nucleoside based PET tracer was [11C]-
Scheme 107
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thymidine218, and later [11C]-5-FU was synthesized219, with the aim to monitor the levels of
1005 5-FU following therapeutic treatments. Starting from the b-(N-Benzoylamino)-a-fluoroacry-
lamide 214, prepared from sodium ethyl-2-fluoro-3-hydroxyacrylate 215, as depicted in
Scheme 115, the introduction of 11C was achieved using [11C]-phosgene, prepared by the
same authors in 2002.220 Acrylamide with the suitable double bond E-stereochemistry 216
was obtained by the irradiation of the Z-isomer 217. The radiochemical yield was about 25%.
1010 11C was initially selected as the preferred radionuclide because it replace a 12C in the
molecular structure, thus not altering the biological behavior of the radiolabeled probe,
compared with its “cold” counterpart. On the contrary, its very short half-life may be a
Scheme 108
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serious drawback, especially in case of slow kinetics, in vivo. For these reasons, attention
was then focused on the preparation of F-18 labeled radiotracers. F-18 has a considerably
1015 longer half-life, which is compatible with the biological half-life of slow kinetics mole-
cules, and at the same time allows for longer radiosynthetic pathways. Furthermore, F-18
is produced efficiently and with high yield, and higher starting activity may also help to
improve the radiopharmaceutical’s availability, Finally, the 110 min half-life of F-18
allows for the radiotracer distribution to other PET centers not equipped with a cyclotron,
1020 thus improving availability and reducing general preparation costs. For instance, the
[11C]-based tracers were later superseded by [18F]-FLT (30-deoxy-30-fluorothymidine),221
which is still one of the most frequently used PET radiotracers in the field of oncology.
[18F]-capecitabine218222, 223 was synthesized, as an enzyme based imaging agent, to
enable non- invasivemonitoring of tumor enzymes (thymidine phosphorylase and uridine phos-
1025 phorylase) (see Scheme 1) and tumor response to capecitabine therapy, using PET technique.
A 2004222 paper reported the synthesis of [18F]-capecitabine 218 through the nucleo-
philic substitution of the 5-nitro group of 20,30-di-O-acetyl-50-deoxy-5-nitro-N4-(penty-
loxycarbonyl)cytidine 219 by reaction with K18F (prepared in a RDS-112 cyclotron) in
the presence of a bicyclic kryptand, Kryptofix 2.2.2 (Scheme 116). The nitro-precursor
1030 was prepared from 5-deoxy-1,2,3-tri-O-acetyl-D-ribose 105 (obtained from D-ribose) and
5-nitrocytosine 220 in 18% overall yield.
A different approach was described by a Korean team223 using as substrate N4-(pen-
tyloxycarbonyl)-cytidine 221, which introduced 18F by direct electrophilic fluorination
with [18F]-F2 generated in a MC-50 cyclotron. The radiochemical yield and radiochemi-
1035 cal purity were 5–15% and >95%, respectively (Scheme 117).
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An attempt to prepare a [18F]-labeled gemcitabine derivative,206 failed at the early
steps of the synthesis since the addition of unlabeled HF (70% in pyridine) to N4-(10-
undecenoyl)-20,20-difluorocytidine led to a mixture of 10-, 9- and 8-fluorinated isomers.
A very interesting enzyme-catalyzed formation of C-F, suitable also to produce
1040 labeled fluoronucleosides was proposed by O’Hagan and coworker in 2003.224–228 They
used the enzyme fluorinase, crude or partially purified, extracted from Streptomyces cat-
tleya. The enzyme is capable to catalyze the synthesis of fluoro compounds, particularly
fluoronucleosides, in the presence of a fluorine donor (lithium, potassium or sodium fluo-
ride) or hydrogen fluoride and of the substrate. (Scheme 118).
1045 The substrate was S-adenosyl-L-methionine (SAM) 222 that, by action of fluorinase,
underwent a nucleophilic substitution (L-methionine 223 as leaving group) leading to 50-
Scheme 111
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fluoro-50-deoxyadenosine 224; the method was also applied to the synthesis of [18F]-50-
fluoro-50-deoxyadenosine.227 Hydrolysis of the N-glycosidic bond by means of nucleo-
side hydrolase from Trypanosoma vivax afforded 5-deoxy-5-[18F]-ribose.221 Starting
1050 from [18F]-50-fluoro-50-deoxyadenosine by means of an enzyme-catalyzed transglycosyla-
tion [18F]- 50-fluoro-50-deoxy-5-fluorouracil was also obtained.227 This and other exam-
ples recently reviewed229 are promising of a wider application of the method, at the
present limited to the fluorination of the 50-position. More recently an enzyme with the
same activity was isolated from the marine derived bacterium Streptomyces
1055 xinghaiensis.230
Conclusion
Fluorinated nucleosides represent an important category of nucleoside analogues
endowed with antitumor and/or antiviral activity. This review focused on antitumor
pyrimidine nucleosides bearing fluorine on the nucleobase or on the glycone.
1060 5-FU 1 is more than 50 years old but it is still used, in combination with other anti-
cancer drugs (for example, avastatatin and oxaliplatin), for the treatment of metastatic
colorectal cancer. A more recent therapeutic indication of 5-FU 1 is the topical use (cream
or solution) for the treatment of skin cancers and Bowen’s disease. Capecitabine (Xeloda)
63 is the most frequently used therapeutic fluoropyrimidine nucleoside, alone or in com-
1065 bination with other drugs and, like other relevant fluoropyrimidines nucleosides ana-
logues, can be regarded as a 5-FU prodrug. Gemcitabine (Gemzar) 151 belongs to the
group of nucleosides fluorinated on the glycone moiety and it is among the ten leading
brands in the global cancer market.
Considering the impressive number of fluorinated pyrimidine nucleosides, a choice
1070 of scope was mandatory, and we decided to select clinically well-established compounds,
and their derivatives designed to improve the pharmacological properties of the parent
compounds. This choice excluded, for example, nucleoside analogues characterized by
the presence of a heteroatom (N, S, Se), different from oxygen in the 5-atoms ring173 or
the carbocyclic analogues,172,231 which are no less interesting than the discussed com-
1075 pounds. Despite the numerous compounds that have received marketing authorization,
the demand for antitumor oral fluoro pyrimidine nucleosides is still of concern; the design
and the synthesis of more selective molecules remains a target of pharmaceutical
research. Such research may develop the possibility of patient-tailored therapy based on
individualized combinations of the described molecules. We hope that the synthetic meth-
1080 ods described in this review, suitably adapted, could be a valuable aid in the development
of new nucleoside analogues.
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